AstraZeneca India Stock Surge: Cancer Drug Ko Mili Mazboori, Share **3.91%** Bhaga!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
AstraZeneca India Stock Surge: Cancer Drug Ko Mili Mazboori, Share **3.91%** Bhaga!
Overview

Arre yaar, AstraZeneca India ke liye ek mast khabar aayi hai! Unke cancer drug Calquence ko CDSCO se approval mil gaya hai, jisse stock seedha **3.91%** upar bhag gaya.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

CDSCO ne AstraZeneca India ko Calquence (Acalabrutinib) 100 mg tablets import karne ki approval de di hai. Ab ye cancer drug pehle kabhi treat na hue Chronic Lymphocytic Leukemia (CLL) ya Small Lymphocytic Lymphoma (SLL) ke patients ke liye bhi use ho sakta hai, jab ise venetoclax ke saath diya jaye.

Market Reaction

Is announcement ke baad toh AstraZeneca Pharma India ka stock jumne laga. BSE par April 10, 2026 ko ye ₹8,366.00 par close hua, matlab lagbhag ₹315.00 ya 3.91% ki badhotri hui. Ye surge dikhata hai ki investors ko company ke oncology business mein kafi dum lag raha hai.

India Ka Cancer Market Kaise Boom Kar Raha Hai?

Aur bhai, India ka oncology market bhi toh rocket banne wala hai! Agle 2025 se 2030 tak ye market $2.35 billion se grow karega, yani 20.0% ki speed se har saal! Cancer cases badh rahe hain, logo mein awareness aa rahi hai aur naye treatments bhi adopt ho rahe hain.

Valuation Aur Competition Ka Game

Company ki valuation dekho toh ₹20,775 se ₹21,123 crore ke aas paas hai. P/E ratio 98.2 se 104.01 ke beech hai. Ye figure industry ke average P/E (39.02) aur Sun Pharma (~34), Dr. Reddy's (~51.61), Cipla (~51.61), Torrent Pharma (~77.78), aur Lupin (~72.22) jaise bade Indian rivals se bahut upar hai. Iska matlab investors ko future growth par full bharosa hai aur wo specialty oncology areas mein company se achhe performance ki ummeed kar rahe hain.

Kya Hai Risks?

Par haan, itni high valuation par thoda dhyan dena zaroori hai. Agar growth expectations poori na hui toh stock gir bhi sakta hai. Competition bhi tagda hai, khaas kar Sun Pharma jaise companies se jinka market mein zabardast hold hai. Aur yaad hai na, pichhle 6 mahine mein stock 12.89% gir bhi gaya tha, toh volatility toh hai hi.

Aage Kya?

Analysts filhal toh 'Buy' recommend kar rahe hain aur global targets bhi growth dikha rahe hain. Innovative oncology drugs par company ka focus India ke badhte cancer market ke liye perfect hai. Company ko naye drugs launch karke aur market share badha kar hi investors ka bharosa bana rahega.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.